§ 01 Overview
Overview
Fixed combination of cagrilintide (amylin analog) and semaglutide, studied for additive weight loss in obesity and T2D.
REDEFINE Phase III program reported ~20–22% weight loss. Results fell short of some investor expectations.
§ 02 Mechanism
Mechanism of action
CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). The two mechanisms produce additive appetite suppression and gastric emptying delay.
- 01Additive weight loss vs. either monotherapy
- 02Improved metabolic markers
- 03Preserved lean mass in some trials
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- Combined vial
- BAC Water
- As per product
- Dose Range
- 2 – 6 mg weekly (cagri + sema)
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate to target over several months.
§ 04 Evidence
Evidence & research
REDEFINE Phase III program reported ~20–22% weight loss. Results fell short of some investor expectations.
FDA Status
Investigational. Expected FDA filing late 2025 / 2026.
§ 05 Stacks
Common stacks
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity - Pharmaceutical Technology
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity Pharmaceutical Technology
The Race to Beat Ozempic Is Getting Weird - Men's Health
The Race to Beat Ozempic Is Getting Weird Men's Health
CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry - Seeking Alpha
CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry Seeking Alpha
Novo Nordisk downgraded at Goldman Sachs on disappointing CagriSema data - Seeking Alpha
Novo Nordisk downgraded at Goldman Sachs on disappointing CagriSema data Seeking Alpha
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide - drugdiscoverytrends.com
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide drugdiscoverytrends.com
Novo Nordisk Resets Obesity Strategy After CagriSema Miss And Vivtex Deal - Yahoo Finance
Novo Nordisk Resets Obesity Strategy After CagriSema Miss And Vivtex Deal Yahoo Finance
Novo downgraded at J.P. Morgan on CagriSema data (NVO:NYSE) - Seeking Alpha
Novo downgraded at J.P. Morgan on CagriSema data (NVO:NYSE) Seeking Alpha
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead. - Reuters
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead. Reuters
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea can be more pronounced than either monotherapy
Contraindications
None specified.